Join the exclusive webinar on the future of AI in healthcare, where leading experts will explore how artificial intelligence is transforming clinical practices, driving innovation, and addressing safety concerns. Gain valuable insights into building a balanced framework that ensures ethical and effective AI adoption in medical settings. Date: 23rd

If you missed yesterday evening’s live seminar on Alpha-Gal Syndrome (AGS), we’re pleased to share that a recorded version is now available for your convenience. 📹 Access the full recording here: https://www.youtube.com/watch?v=5KFYWFg1ydY Why This Matters: AGS is a serious but often overlooked allergic condition triggered by tick bites, leading t

Introduction Atopic dermatitis (AD) is a chronic inflammatory dermatosis affecting a significant portion of both pediatric and adult populations worldwide. Moderate-to-severe cases are often associated with substantial physical and psychological burden. Despite advancements in treatment, including the introduction of biologics like dupilumab, a pro

Introduction Atopic dermatitis (AD) is a chronic, inflammatory skin disease marked by intense pruritus, skin barrier disruption, and a cycle of flares and remissions. While topical corticosteroids (TCS) remain a cornerstone of treatment, many patients with moderate-to-severe disease fail to achieve adequate control. The advent of Janus kinase (JAK)

Introduction: Alopecia Areata (AA) is an autoimmune disease possessing immunoinflammatory mechanisms that lead to hair loss from the scalp, face, and/or body (1). Among affected patients, approximately 10-35% experience progression to more severe forms of AA (1). Moderate to severe AA has been refractory to treatment, although Janus Kinase inhibito

Introduction Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis, characterized by joint pain, stiffness, and swelling. The management of PsA often requires a multifaceted approach, including pharmacological interventions. This case study summarizes the findings from a study assessing the long-term efficacy and s

The KEEPsAKE 1 trial is a phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of risankizumab, a biological therapy targeting interleukin 23, in patients with active psoriatic arthritis (PsA) who have had inadequate responses or intolerance to conventional synthetic disease-modifying antirheumati

Introduction: Chronic spontaneous urticaria (CSU) is a persistent inflammatory skin disorder marked by recurrent, unpredictable episodes of hives (wheals), pruritus, and sometimes angioedema lasting longer than six weeks, affecting up to 0.1% to 1.4% of the global population (1). It significantly impairs quality of life, disrupts sleep, and leads t

Introduction: Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, is a common condition characterized by recurrent, pruritic, erythematous wheals persisting for more than six weeks without a specific known cause. CSU affects approximately 0.5% to 1.8% of the adult population and can significantly impact quality of life